COMMUNIQUÉS West-GlobeNewswire

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
01/10/2026
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
01/10/2026
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major [...]
Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
01/10/2026
Clover’s portfolio combines high-choice PPO access and meaningful member benefits with a Clover Assistant-powered care model WILMINGTON, Del., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: [...]
Teal Lights and Shared Stories: The Facial Pain Association Marks Facial Pain Awareness Month This October
01/10/2026
Landmarks worldwide will glow teal in solidarity. The month also features patient stories, educational resources, and ways for everyone to get involved SUWANEE, Ga., Oct. 01, 2026 (GLOBE NEWSWIRE) -- October is Facial [...]
Stryker to announce third quarter 2026 financial results
01/10/2026
Portage, Michigan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, October 29, 2026, to discuss its third quarter 2026 financial results. The live [...]
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
01/10/2026
FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management. Key Highlights: Commercial Acceleration: Daxor to [...]
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
01/10/2026
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY- [...]
Helus Pharma Announces Completion of Legal Name Change
01/10/2026
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel [...]
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
01/10/2026
Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, [...]
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
01/10/2026
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to [...]
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
01/10/2026
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the [...]
Allogenetics Appoints Dr. Olaf Schermeier as Chairman of the Advisory Board
01/10/2026
Hanover, Germany, October 01, 2026 – Allogenetics today announced the appointment of Olaf Schermeier, PhD, as Chairman of its Advisory Board. Dr. Schermeier brings more than 25 years of industry experience, including [...]
Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
01/10/2026
In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in [...]
Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
01/10/2026
Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Numab Therapeutics (“Numab [...]
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
01/10/2026
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress [...]
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people [...]
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
01/10/2026
Professional microneedling and nano-needling device launches in UK, Ireland, Germany, France, Spain and Portugal LONG BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems (Nasdaq: SKIN), home to flagship [...]

Pages